Aduhelm

Aduhelm is a medication approved to treat Alzheimer's disease, a condition that affects memory and thinking skills. It works by targeting and removing amyloid beta plaques, abnormal protein deposits in the brain that are thought to contribute to the disease's progression. The goal of Aduhelm is to slow cognitive decline, though its approval has been controversial due to mixed evidence about its effectiveness. It is administered through intravenous infusions and is intended for patients in the early stages of Alzheimer's. As with any treatment, potential benefits and risks should be discussed with a healthcare professional.